CN
Home/Newsroom/News

News 2018-04-23

Porton Pharma Solutions and Codexis Launch Global Partnership

April 23, 2018, Chongqing, China and Redwood City, Calif.–Porton Pharma Solutions, Ltd.(SZSE: 300363, “Porton”) and Codexis, Inc.(NASDAQ: CDXS, “Codexis”) announce a strategic collaboration to deploy Codexis’world-leading biocatalyst technology within Porton’s global custom intermediateand active pharmaceutical ingredients (API) development and manufacturing business. The partnership will accelerate the creation and commercialization of new, low-cost, sustainable manufacturing processes, exploiting the benefits of biocatalysts to a growing number of the world’s small molecule pharmaceuticals.





Under the terms of the collaboration, Codexis will license core elements of its biocatalyst technologies to Porton, including its proprietary biocatalyst libraries, high-throughput screening and enzyme manufacturing know-how. Codexis will also provide preferential access to its CodeEvolver® protein engineering platform technology for the creation of new biocatalytic process solutions. Porton will install new operations to drive adoption and optimal application of these biocatalyst technologies into its custom contract development and manufacturing(CDMO) offerings to global pharmaceutical customers. Additionally, Porton pledges financial commitments to utilize Codexis’ CodeEvolver® protein engineering platform technology.
 



The partnership reinforces the benefits of reduced costs, enhanced sustainability and improved product quality that biocatalysts can deliver to the manufacturing of the world’s small molecule pharmaceuticals. These benefits are already impacting a growing set of the world’s drug manufacturing processes and have earned Codexis three U.S. EPA Presidential Green Chemistry Challenge awards for its biocatalysts’ contributions in these commercial-scale drug manufacturing innovations.
 



“Technological leadership is central to our strategy to grow and deliver value to our pharmaceutical clients around the globe,” said Oliver Ju, chairman and CEO at Porton Pharma Solutions. “We believe that biocatalysis is the most impactful technology to improve the future of pharmaceutical manufacturing, and there is not a more capable player to partner with than Codexis.”

“We are delighted to establish this unique partnership with Porton,” said John Nicols, president and CEO of Codexis. “Given Porton’s significant and fast-growing presence as a leading global CDMO, we will now be able to reach a greater share of the world’s pharmaceutical manufacturing market.”



About Codexis


Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see www.codexis.com.


Codexis Contacts:


Investors
LHA Investor Relations
Jody Cain, (310) 691-7100
jcain@lhai.com

About Porton
Porton is an industry-leading partner and provider of custom active pharmaceutical ingredient (API) development and manufacturing services to the global drug industry (SZSE, Stock Code 300363). Backed by more than 1,700 customer-centric employees, cutting-edge Process R&D Centers, USFDA and PMDA-inspected cGMP production sites and marketing offices located across Asia, North America and Europe, Porton helps its customers more efficiently deliver improved health outcomes to their patients through chemical process innovation, rapid scale-up and high-quality, cost-effective manufacture of APIs and/or drug intermediates. Learn more by visiting www.porton.cn.
Others
More

News 2024-10-31

Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai

Recently, Porton Pharma has achieved a significant capacity breakthrough at its GMP manufacturing facility in Fengxian, Shanghai, China, further enhancing its production capabilities and technological strength in new modality areas such as peptide and oligonucleotide drugs. This upgrade represents an important step in Porton's commitment to becoming a leading global CDMO company.

News 2024-10-24

Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar

On October 24, 2024, Porton Pharma SolutionsLtd. ("Porton") announced a strategic partnership with Shanghai InnoStar Bio-tech Co., Ltd. ("InnoStar") in Shanghai. The distinguished signing ceremony was attended by Mr. Ju Nianfeng, Chairman and CEO of Porton; Dr. Chang Yan, President of InnoStar; Ms. Pi Wei, Deputy General Manager of Porton; Ms. Fan Meng, Deputy General Manager of the Sales & Marketing Center, Dr. Fang Xin, Senior Director of Non-clinicalPharmacology BU at InnoStar, and Ms. Zhao Jie, Marketing Associate Director at InnoStar.
Become part of Porton' s community to access personalized insights and resources.
Submit
By clicking "Submit" you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.
US: (609) 860-1300
CN: (86) 23-8608-3200

ⓒ 2024 PORTON Legal Notices | Porton Privacy

This website contains information on products which are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your countries. Please be aware that we do not take any responsibity for accessing suchinlomaon which may not compy wih anylegal process,regulaion,registraton or usage in the counry of your origin.

Become part of Porton' s community to access personalized insights and resources.
Submit
By clicking "Submit" you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

Copyright © PORTON 2024. All Rights Reserved.

Legal Notices Porton Privacy
US: (609) 860-1300
CN: (86) 23-8608-3200